As I said current board has their chance..JG rules here ..CG is...

As I said current board has their chance..JG rules here ..CG is a drug expert but no commerical experience...market wants contact and $$ when needed ...and clearly these guys are not capable ...

They could not get one partner to stump up $15-$20m before the results...out of 50 discussions... obviously not good enough ...

Letter is well written and states the facts ..but us holders have had too much faith in current board
..

Below is from the letter and is perfect example of a decent FU over time...

Why Change is Needed Now



When assessing the board's performance, the most important metric for shareholders is share price performance. Despite all of the drug development experience touted by the current leadership, the company’s current leadership has presided over significant value destruction, even without taking into account the failed trial:

• Since Dr Charmaine Gittleson became Chair, the share price has plummeted by approximately 70% (not including the post-Phase II Topline results trading).

• Under Dr James Garner’s tenure as CEO, the share price has fallen 33% (not including the post-Phase II Topline results trading) over just 16 months in the lead-up to the Topline results release.

This is similar to the disappointing performance of other companies highlighted in the directors' bios, where they were involved immediately prior to and / or during their tenure with Percheron. Interestingly, the logos of these companies—Patrys Limited, NeuroBo, and Kazia Therapeutics—are not displayed.



At the recent AGM, shareholders delivered a clear message of dissatisfaction by voting against the remuneration report and issuing a first strike. This reflected a growing concern about disproportionate pay and bonuses awarded to the current Board, despite poor share price performance. The Board’s response was to edit out critical feedback raised during the AGM from the video shared with shareholders—yet another example of their reluctance to face accountability